The findings of an international study led by the Centenary Institute suggests that the possibility of high-risk drinkers developing alcohol-induced cirrhosis is in part related to genetic factors.
“Only a small proportion of high-risk drinkers, about 15 percent, actually develop cirrhosis but those who do are at high risk of death and require substantial health-care support,” said senior author of the published study Clinical Associate Professor Devanshi Seth, Head of the Centenary Institute Alcoholic Liver Disease Research Program and also affiliated with Drug Health Services, Royal Prince Alfred Hospital, Sydney Local Health District.
“We wanted to see if certain high-risk drinkers had a genetic predisposition for alcohol-induced cirrhosis. High-risk drinking is chronic alcohol use above recommended guidelines,” said Clinical Associate Professor Seth.
Reported in the science journal Hepatology, the study was undertaken by a multi-national GenomALC Consortium involving the Southern California Institute for Research and Education (SCIRE) and other research collaborators.
Identified by the study researchers is a new gene associated with alcohol-induced cirrhosis. The novel FAF2 gene is associated with a reduced cirrhosis risk for heavy drinkers. Also confirmed by the study were four additional genes, three previously found to be associated with an increased risk and one with reduced risk of cirrhosis in heavy drinkers.
“Interestingly, a commonality of these genes, including the novel FAF2, is that they appear to affect the lipid (fat) metabolism pathway,” said Clinical Associate Professor Seth.
“The findings are important as due to heavy drinking, it is the build-up of lipid droplets in the liver, that can cause inflammation, and which may then lead to serious liver complications such as cirrhosis in some drinkers,” she said.
The researchers believe that the identified genes are influencing the body’s ability to regulate lipid droplets in the liver and are therefore influencing cirrhosis risk levels.
“This new understanding opens the door to the future development of exciting new drug treatments that can potentially target these specific genes and lipid processes, and reduce the chances of at-risk individuals contracting this devastating disease,” said Dr. Timothy Morgan, co-senior author of the study and researcher at the SCIRE.
Source: Read Full Article